As of May 15, 2025, the Dexcom stock's P/E ratio is 63.46. This takes into account the latest EPS of $1.35 and stock price of $85.67. The PE ratio has increased by 22% from its last 4 quarters average of 52.2.
The PE ratio of Dexcom has averaged 124.01 over the last seven years. The current price-to-earnings ratio of 63.46 is 49% less than the historical average. Analyzing the last seven years, DXCM's PE ratio reached its highest point in the Sep 2018 quarter at 298, when the price was $35.76 and the EPS was $0.12. The lowest point was recorded in the Sep 2024 quarter, when it reached 38.53 with a price of $67.04 and an EPS of $1.74.
Maximum annual increase: 278.63% in 2021
Maximum annual decrease: -67.58% in 2020
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 53.27 | -39.9% | $77.77 | $1.46 |
2023 | 88.64 | -31.12% | $124.09 | $1.4 |
2022 | 128.68 | -46.32% | $113.24 | $0.88 |
2021 | 239.71 | 278.63% | $134.24 | $0.56 |
2020 | 63.31 | -67.58% | $92.43 | $1.46 |
2019 | 195.3 | N/A | $54.69 | $0.28 |
2018 | N/A | N/A | $29.95 | -$0.36 |
2017 | N/A | N/A | $14.35 | -$0.15 |
2016 | N/A | N/A | $14.93 | -$0.2 |
2015 | N/A | N/A | $20.48 | -$0.18 |
2014 | N/A | N/A | $13.76 | -$0.08 |
2013 | N/A | N/A | $8.85 | -$0.11 |
2012 | N/A | N/A | $3.4 | -$0.2 |
2011 | N/A | N/A | $2.33 | -$0.17 |
2010 | N/A | N/A | $3.41 | -$0.24 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 50.59 | -5.03% | $68.29 | $1.35 |
Dec 2024 | 53.27 | 38.26% | $77.77 | $1.46 |
Sep 2024 | 38.53 | -41.89% | $67.04 | $1.74 |
Jun 2024 | 66.3 | -21.13% | $113.38 | $1.71 |
Mar 2024 | 84.06 | -5.17% | $138.7 | $1.65 |
Dec 2023 | 88.64 | -6.89% | $124.09 | $1.4 |
Sep 2023 | 95.2 | -31.1% | $93.3 | $0.98 |
Jun 2023 | 138.18 | -9.61% | $128.51 | $0.93 |
Mar 2023 | 152.87 | 18.8% | $116.18 | $0.76 |
Dec 2022 | 128.68 | 0.66% | $113.24 | $0.88 |
Sep 2022 | 127.84 | 2.91% | $80.54 | $0.63 |
Jun 2022 | 124.22 | -34.93% | $74.53 | $0.6 |
Mar 2022 | 190.9 | -20.36% | $127.9 | $0.67 |
Dec 2021 | 239.71 | 192.79% | $134.24 | $0.56 |
Sep 2021 | 81.87 | 25.01% | $136.72 | $1.67 |
DXCM's current PE ratio is under its 3, 5 and 10-year averages.
DXCM's PE ratio is above its peer stocks JNJ and ABT. Dexcom's current PE ratio of 63.46 is more than the average of its peers, which is 22.8.
Stock name | PE ratio | Market cap |
---|---|---|
EW Edwards Lifesciences Corp | 10.94 | $45.1B |
JNJ Johnson & Johnson | 16.51 | $359.97B |
ABT Abbott Laboratories | 17.27 | $232.01B |
MDT Medtronic plc | 26.02 | $110.44B |
WST West Pharmaceutical Services Inc | 32.82 | $15.14B |
BDX Becton Dickinson & Co | 33.26 | $49.37B |
DXCM Dexcom Inc | 63.46 | $33.59B |
TNDM Tandem Diabetes Care Inc | N/A | $1.51B |
QDEL Quidel Corp | N/A | $2.23B |
The price to earnings ratio for DXCM stock is 63.46 as of May 15, 2025.
As an average over the last 3 years, DXCM stock has a PE ratio of 95.7.
As an average over the last 5 years, DXCM stock has a PE ratio of 109.74.
Over the last seven years, the quarterly PE ratio reached its highest level at 298 in the Sep 2018 quarter.
DXCM's price to earnings ratio is currently 49% below its 7-year historical average.
The P/E ratio is calculated by dividing the latest price of a stock by its trailing twelve months EPS. As of today (May 15, 2025), Dexcom's share price is $85.67. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.35. Therefore, Dexcom's price to earnings ratio for today is 63.46. PE RATIO(63.46) = STOCK PRICE($85.67) / TTM EPS($1.35)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.